Literature DB >> 29091428

Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors.

Predrag Kalaba1, Nilima Y Aher1, Marija Ilić1, Vladimir Dragačević1, Marcus Wieder1, Andras G Miklosi1, Martin Zehl2, Judith Wackerlig1, Alexander Roller3, Tetyana Beryozkina4, Bojana Radoman1, Sivaprakasam R Saroja5, Wolfgang Lindner2, Eduardo Perez Gonzalez6, Vasiliy Bakulev4, Johann Jakob Leban1, Harald H Sitte7, Ernst Urban1, Thierry Langer1, Gert Lubec8.   

Abstract

Modafinil is a wake promoting compound with high potential for cognitive enhancement. It is targeting the dopamine transporter (DAT) with moderate selectivity, thereby leading to reuptake inhibition and increased dopamine levels in the synaptic cleft. A series of modafinil analogues have been reported so far, but more target-specific analogues remain to be discovered. It was the aim of this study to synthesize and characterize such analogues and, indeed, a series of compounds were showing higher activities on the DAT and a higher selectivity toward DAT versus serotonin and norepinephrine transporters than modafinil. This was achieved by substituting the amide moiety by five- and six-membered aromatic heterocycles. In vitro studies indicated binding to the cocaine pocket on DAT, although molecular dynamics revealed binding different from that of cocaine. Moreover, no release of dopamine was observed, ruling out amphetamine-like effects. The absence of neurotoxicity of a representative analogue may encourage further preclinical studies of the above-mentioned compounds.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29091428     DOI: 10.1021/acs.jmedchem.7b01313

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Monoamine transporters: structure, intrinsic dynamics and allosteric regulation.

Authors:  Mary Hongying Cheng; Ivet Bahar
Journal:  Nat Struct Mol Biol       Date:  2019-07-03       Impact factor: 15.369

2.  Evaluation of Urea-Based Inhibitors of the Dopamine Transporter Using the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.

Authors:  Md Ashraf-Uz-Zaman; Guangchen Ji; Dalton Tidwell; Linda Yin; Smathorn Thakolwiboon; Jie Pan; Riley Junell; Zach Griffin; Sadisna Shahi; Derek Barthels; Md Sanaullah Sajib; Paul C Trippier; Constantinos M Mikelis; Hiranmoy Das; Mirla Avila; Volker Neugebauer; Nadezhda A German
Journal:  ACS Chem Neurosci       Date:  2022-01-03       Impact factor: 5.780

3.  The Novel Analogue of Modafinil CE-158 Protects Social Memory against Interference and Triggers the Release of Dopamine in the Nucleus Accumbens of Mice.

Authors:  Karl Ebner; Simone B Sartori; Rita Murau; Fabian Kopel; Predrag Kalaba; Vladimir Dragačević; Johann J Leban; Nicolas Singewald; Mario Engelmann; Gert Lubec
Journal:  Biomolecules       Date:  2022-03-27

4.  Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding.

Authors:  Renee A Rotolo; Predrag Kalaba; Vladimir Dragacevic; Rose E Presby; Julia Neri; Emily Robertson; Jen-Hau Yang; Merce Correa; Vasiliy Bakulev; Natalia N Volkova; Christian Pifl; Gert Lubec; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2020-08-07       Impact factor: 4.530

5.  Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.

Authors:  JoLynn B Giancola; Alessandro Bonifazi; Jianjing Cao; Therese Ku; Alexandra J Haraczy; Jenny Lam; Rana Rais; Mark A Coggiano; Gianluigi Tanda; Amy Hauck Newman
Journal:  Eur J Med Chem       Date:  2020-08-09       Impact factor: 6.514

6.  New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.

Authors:  Amy Hauck Newman; Therese Ku; Chloe J Jordan; Alessandro Bonifazi; Zheng-Xiong Xi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2021-01-06       Impact factor: 16.459

7.  Differential Effects of Novel Dopamine Reuptake Inhibitors on Interference With Long-Term Social Memory in Mice.

Authors:  Judith Camats-Perna; Predrag Kalaba; Karl Ebner; Simone B Sartori; Harish Vuyyuru; Nilima Y Aher; Vladimir Dragačević; Nicolas Singewald; Mario Engelmann; Gert Lubec
Journal:  Front Behav Neurosci       Date:  2019-04-11       Impact factor: 3.558

8.  A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions.

Authors:  Shima Kouhnavardi; Alev Ecevitoglu; Vladimir Dragačević; Fabrizio Sanna; Edgar Arias-Sandoval; Predrag Kalaba; Michael Kirchhofer; Jana Lubec; Marco Niello; Marion Holy; Martin Zehl; Matthias Pillwein; Judith Wackerlig; Rita Murau; Andrea Mohrmann; Kathryn R Beard; Harald H Sitte; Ernst Urban; Claudia Sagheddu; Marco Pistis; Roberto Plasenzotti; John D Salamone; Thierry Langer; Gert Lubec; Francisco J Monje
Journal:  Biomolecules       Date:  2022-06-24

Review 9.  Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder.

Authors:  Gianluigi Tanda; Melinda Hersey; Briana Hempel; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Curr Opin Pharmacol       Date:  2020-09-11       Impact factor: 5.547

10.  Reinstatement of synaptic plasticity in the aging brain through specific dopamine transporter inhibition.

Authors:  Jana Lubec; Predrag Kalaba; Ahmed M Hussein; Daniel Daba Feyissa; Mohamed H Kotob; Rasha R Mahmmoud; Oliver Wieder; Arthur Garon; Claudia Sagheddu; Marija Ilic; Vladimir Dragačević; Anita Cybulska-Klosowicz; Martin Zehl; Judith Wackerlig; Simone B Sartori; Karl Ebner; Shima Kouhnavardi; Alexander Roller; Natalie Gajic; Marco Pistis; Nicolas Singewald; Johann Jakob Leban; Volker Korz; Jovana Malikovic; Roberto Plasenzotti; Harald H Sitte; Francisco J Monje; Thierry Langer; Ernst Urban; Christian Pifl; Gert Lubec
Journal:  Mol Psychiatry       Date:  2021-12       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.